MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa.

School of Medical Sciences, University of NSW, Sydney, Australia.
Modern Pathology (Impact Factor: 6.36). 10/2009; 22(12):1588-99. DOI: 10.1038/modpathol.2009.130
Source: PubMed

ABSTRACT O(6)-methylguanine DNA methyltransferase (MGMT) is a DNA repair protein that restores mutagenic O(6)-methylguanine to guanine. MGMT methylation is frequently observed in sporadic colorectal cancer and was recently correlated with the C>T allele at SNP rs16906252, within the transcriptional enhancer element of the promoter. MGMT methylation has also been associated with KRAS mutations, particularly G>A transitions. We studied 1123 colorectal carcinoma to define the molecular and clinicopathological profiles associated with MGMT methylation. Furthermore, we assessed factors contributing to MGMT methylation in the development of colorectal cancer by studying the allelic pattern of MGMT methylation using SNP rs16906252, and the methylation status of neighbouring genes within 10q26 in selected tumours and matched normal colonic mucosa. MGMT methylation was detected by combined bisulphite restriction analysis in 28% of tumours and was associated with a number of characteristics, including CDKN2A methylation, absent lymphovascular space invasion and KRAS mutations (but not specifically with KRAS G>A transitions). In a multivariate analysis adjusted for age and sex, MGMT methylation was associated with the T allele of SNP rs16906252 (P<0.0001, OR 5.5, 95% CI 3.8-7.9). Low-level methylation was detected by quantitative methylation-specific PCR in the normal colonic mucosa of cases, particularly those with a correspondingly methylated tumour, as well as controls without neoplasia, and this was also associated with the C>T SNP. We show that the T allele at SNP rs16906252 is a key determinant in the onset of MGMT methylation in colorectal cancer, whereas the association of methylation at MGMT and CDKN2A suggests that these loci may be targets of a common mechanism of epigenetic dysregulation.

Download full-text


Available from: Robyn Ward, Apr 14, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our research group has developed the micro unit operation (MUO) and the continuous flow chemical processing (CFCP) methods, 2D and 3D multi-phase layered flow network, and the thermal lens microscope (TLM), for design, control, and ultra sensitive detection of non-fluorescent molecules at sub-single molecule (y-mole) levels. These methods have enabled integration of any type of chemical system on microchips almost freely. The performances of those integrated micro systems, such as processing time, throughput, detection limit, etc., were proved to be two to three orders superior to conventional systems. High throughput processing of the micro immunoassay systems for diagnosis and the micro bioassay systems for toxic screenings are the most typical examples for human and life science application. The micro bioassay system is introduced as an example of our integration technique for complicated systems. Furthermore, bio-MEMS using living cell and the Japanese national research projects on microchip chemical technologies are also introduced briefly.
    Micromechatronics and Human Science, 2002. MHS 2002. Proceedings of 2002 International Symposium on; 02/2002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Germline sequence mutations in tumour suppressor genes can cause cancer predisposition syndromes. More recently, epimutations have also been proposed to cause at least one such syndrome, hereditary non-polyposis colorectal cancer (HNPCC). 'Epigenetic predisposition', is defined as an inherited propensity to an altered epigenetic state in normal tissues that confers a predisposition to disease. Genetic sequence variations acting in cis or trans may contribute to epigenetic variations. Understanding the origin of epimutations will inform cancer risk assessment and will also aid the design and application of new therapies that target the epigenome.
    Current opinion in genetics & development 03/2010; 20(3):290-8. DOI:10.1016/j.gde.2010.02.005 · 8.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Promoter methylation of colorectal cancer-related genes were examined with respect to phenotype and tumor progression. We assayed promoter methylation of 11 genes including established CpG island methylator phenotype (CIMP) markers (MLH1, MINT1, MINT2, MINT31, p16 ( INK4a ), p14 ( ARF ), and CACNA1G) and four genes (COX2, DAPK, MGMT, and APC) frequently methylated in colorectal cancer in 285 patients with sporadic colorectal cancer. CIMP+ tumors were more than two times more frequent among high-frequency microsatellite instability tumors (MSI-H) than in tumors without MSI (P < or = .0001-.002). COX2 and DAPK methylation were significantly associated with CIMP+ and MSI. KRAS showed tendency toward more frequent codon 12-13 mutations identified in tumors with APC and p16 ( INK4a ) methylation than in those with unmethylation (P = .033 and .05, respectively). Additionally, tumors with synchronous adenoma were associated with p16 ( INK4a ) methylation (P = .004). The p16 ( INK4a ) methylation was significantly associated with poor overall and disease-free survival in 131 rectal cancer patients who underwent curative operation, according to multivariate analyses (relative risk [RR] = 0.317 and 0.349; P = .033 and .024, respectively). Specifically, in 175 stage II and III patients receiving adjuvant-based fluoropyrimidine chemotherapy, p16 ( INK4a ) methylation and MINT31 unmethylation showed a significant or tendency toward an association with recurrence and DFS (P = .007-.032). The study suggests that specific CIMP markers, such as p16 ( INK4a ) and MINT31, should be further verified as potential epigenetic targets for the design of efficient chemotherapy regimens. We also identified a subset of colorectal cancer, possibly comprising APC methylation-KRAS mutation-p16 ( INK4a ) methylation.
    Annals of Surgical Oncology 07/2010; 17(7):1767-76. DOI:10.1245/s10434-009-0901-y · 3.94 Impact Factor